A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

NCT00225550 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: ADH -1 (Exherin™)

Sponsor

Adherex Technologies, Inc.